Advertisement

Topics

Imbruvica finds new use as GvHD drug

10:55 EDT 2 Aug 2017 | BioPharmaDive

The FDA gives the go-ahead to AbbVie and J&J's blood cancer drug Imbruvica as a treatment for chronic graft-vs-host disease. 

Original Article: Imbruvica finds new use as GvHD drug

NEXT ARTICLE

More From BioPortfolio on "Imbruvica finds new use as GvHD drug"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...